Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02192294 | Absolute Bioavailability Of Bosutinib | PHASE1 | COMPLETED | 14 | — | — | Aug 1, 2014 | Oct 1, 2014 | Oct 31, 2014 | 1 | United Kingdom |
AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.
| Arm | Type | Description |
|---|---|---|
| Bosutinib | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Oral Bosutinib | DRUG | a single dose of 500 mg oral bosutinib |
| Intravenous infusion of bosutinib | DRUG | a single dose of 120 mg of bosutinib intravenous infusion (1 hour) |
Inclusion Criteria: * Healthy male and/or female subjects (of non-childbearing potential). * Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study. * Subjects who are willing and able to comply with al...